Skip to content
2000
Volume 33, Issue 3
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background and Objective

Colorectal Cancer (CRC) affects the colon and rectum part of the digestive system and is a significant global health concern, with approximately 1.1 million new cases annually. It ranks second in cancer-related deaths. Studies have shown future projections of CRC cases to enhance at a worrisome rate, estimating 3.2 million new cases and 1.6 million deaths worldwide by 2040. Studies have shown the downregulation of TMEM236 in CRC, and this study aimed to find the agonist to restore the function of TMEM236 the drug repurposing method.

Methods

The different molecular and structural level analyses were performed to understand how the TMEM236 expression can be restored. To obtain the molecular level data, the following analyses were employed to understand the binding affinity and agonistic behaviour of the screened drugs: molecular docking, oral toxicity prediction, Molecular Dynamics (MD) simulation, Free Energy Landscape (FEL) analysis, and g_mmpbsa.

Results

The molecular docking, oral toxicity, and molecular interaction analyses have identified db06435, db05423, and db15197 drugs from the DrugBank database to either belong to an approved or investigational class of drugs as a potential agonist for TMEM236. The MD simulation and PCA analysis had shown db05423 (ORG-317) to exhibit stable interaction with TMEM236 protein. Similar results were obtained through FEL analysis.

Conclusion

The downregulation of TMEM236 expression and its constant binding affinity with db05423 during MD simulation suggest that this drug may restore the diminished function and expression of TMEM236. Additionally, it could function as an agonist and can be used for CRC treatment.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673322888240718104833
2024-12-03
2026-02-23

  • From This Site

    /content/journals/cmc/10.2174/0109298673322888240718104833
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. CervantesA. AdamR. RosellóS. ArnoldD. NormannoN. TaïebJ. SeligmannJ. De BaereT. OsterlundP. YoshinoT. MartinelliE. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.Ann. Oncol.2023341103210.1016/j.annonc.2022.10.00336307056
     [Google Scholar]
  2. AkimotoN. UgaiT. ZhongR. HamadaT. FujiyoshiK. GiannakisM. WuK. CaoY. NgK. OginoS. Rising incidence of early-onset colorectal cancer - A call to action.Nat. Rev. Clin. Oncol.202118423024310.1038/s41571‑020‑00445‑133219329
     [Google Scholar]
  3. MorganE. ArnoldM. GiniA. LorenzoniV. CabasagC.J. LaversanneM. VignatJ. FerlayJ. MurphyN. BrayF. Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN.Gut202372233834410.1136/gutjnl‑2022‑32773636604116
     [Google Scholar]
  4. MauryaN.S. KushwahaS. ChawadeA. ManiA. Transcriptome profiling by combined machine learning and statistical R analysis identifies TMEM236 as a potential novel diagnostic biomarker for colorectal cancer.Sci. Rep.20211111430410.1038/s41598‑021‑92692‑034253750
     [Google Scholar]
  5. HrašovecS. HauptmanN. GlavačD. JelencF. Ravnik-GlavačM. TMEM25 is a candidate biomarker methylated and down-regulated in colorectal cancer.Dis. Markers20133429310410.1155/2013/42789023324576
     [Google Scholar]
  6. ZhouX. PopescuN.C. KleinG. ImrehS. The interferon-α responsive gene TMEM7 suppresses cell proliferation and is downregulated in human hepatocellular carcinoma.Cancer Genet. Cytogenet.2007177161510.1016/j.cancergencyto.2007.04.00717693185
     [Google Scholar]
  7. CuajungcoM.P. PodevinW. ValluriV.K. BuiQ. NguyenV.H. TaylorK. Abnormal accumulation of human transmembrane (TMEM)-176A and 176B proteins is associated with cancer pathology.Acta Histochem.2012114770571210.1016/j.acthis.2011.12.00622244448
     [Google Scholar]
  8. FinaD. FranchiL. CarusoR. PelusoI. NaccariG.C. BellinviaS. TestiR. PalloneF. MonteleoneG. 5-aminosalicylic acid enhances anchorage-independent colorectal cancer cell death.Eur. J. Cancer200642152609261610.1016/j.ejca.2006.03.03016914308
     [Google Scholar]
  9. Reinacher-SchickA. SchoeneckA. GraevenU. Schwarte-WaldhoffI. SchmiegelW. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells.Carcinogenesis200324344345110.1093/carcin/24.3.44312663503
     [Google Scholar]
  10. BrimblecombeR. Mesalazine: A global safety evaluation.Scand. J. Gastroenterol. Suppl.19901726610.3109/003655290090919151972297
     [Google Scholar]
  11. ChinC.C. LiJ.M. LeeK.F. HuangY.C. WangK.C. LaiH.C. ChengC.C. KuoY.H. ShiC.S. Selective β2-AR blockage suppresses colorectal cancer growth through regulation of EGFR-Akt/ERK1/2 signaling, G1-phase arrest, and apoptosis.J. Cell. Physiol.2016231245947210.1002/jcp.2509226189563
     [Google Scholar]
  12. JumperJ. EvansR. PritzelA. GreenT. FigurnovM. RonnebergerO. TunyasuvunakoolK. BatesR. ŽídekA. PotapenkoA. BridglandA. MeyerC. KohlS.A.A. BallardA.J. CowieA. Romera-ParedesB. NikolovS. JainR. AdlerJ. BackT. PetersenS. ReimanD. ClancyE. ZielinskiM. SteineggerM. PacholskaM. BerghammerT. BodensteinS. SilverD. VinyalsO. SeniorA.W. KavukcuogluK. KohliP. HassabisD. Highly accurate protein structure prediction with AlphaFold.Nature2021596787358358910.1038/s41586‑021‑03819‑234265844
     [Google Scholar]
  13. LaskowskiR.A. MacArthurM.W. MossD.S. ThorntonJ.M. PROCHECK: A program to check the stereochemical quality of protein structures.J. Appl. Cryst.199326228329110.1107/S0021889892009944
     [Google Scholar]
  14. MorrisG.M. HueyR. LindstromW. SannerM.F. BelewR.K. GoodsellD.S. OlsonA.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.J. Comput. Chem.200930162785279110.1002/jcc.2125619399780
     [Google Scholar]
  15. YuW. MacKerellA.D. Computer-aided drug design methods.Mol. Biol.201715208510610.1007/978‑1‑4939‑6634‑9_527873247
     [Google Scholar]
  16. WishartD.S. FeunangY.D. GuoA.C. LoE.J. MarcuA. GrantJ.R. SajedT. JohnsonD. LiC. SayeedaZ. AssempourN. IynkkaranI. LiuY. MaciejewskiA. GaleN. WilsonA. ChinL. CummingsR. LeD. PonA. KnoxC. WilsonM. DrugBank 5.0: A major update to the DrugBank database for 2018.Nucleic Acids Res.201846D1D1074D108210.1093/nar/gkx103729126136
     [Google Scholar]
  17. TianW. ChenC. LeiX. ZhaoJ. LiangJ. CASTp 3.0: Computed atlas of surface topography of proteins.Nucleic Acids Res.201846W1W363W36710.1093/nar/gky47329860391
     [Google Scholar]
  18. TrottO. OlsonA.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.J. Comput. Chem.201031245546110.1002/jcc.2133419499576
     [Google Scholar]
  19. DrwalM.N. BanerjeeP. DunkelM. WettigM.R. PreissnerR. ProTox: A web server for the in silico prediction of rodent oral toxicity.Nucleic Acids Res.201442W1W53W5810.1093/nar/gku40124838562
     [Google Scholar]
  20. MerdekawatiF. In silico study of pyrazolylaminoquinazoline toxicity by lazar, protox, and admet predictor.J. Appl. Pharm. Sci.20188911912910.7324/JAPS.2018.8918
     [Google Scholar]
  21. BanerjeeP. EckertA.O. SchreyA.K. PreissnerR. ProTox-II: A webserver for the prediction of toxicity of chemicals.Nucleic Acids Res.201846W1W257W26310.1093/nar/gky31829718510
     [Google Scholar]
  22. Van Der SpoelD. LindahlE. HessB. GroenhofG. MarkA.E. BerendsenH.J.C. GROMACS: Fast, flexible, and free.J. Comput. Chem.200526161701171810.1002/jcc.2029116211538
     [Google Scholar]
  23. HuangJ. MacKerellA.D.Jr. CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data.J. Comput. Chem.201334252135214510.1002/jcc.2335423832629
     [Google Scholar]
  24. VanommeslaegheK. HatcherE. AcharyaC. KunduS. ZhongS. ShimJ. DarianE. GuvenchO. LopesP. VorobyovI. MackerellA.D.Jr. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields.J. Comput. Chem.201031467169010.1002/jcc.2136719575467
     [Google Scholar]
  25. AndersenH.C. Molecular dynamics simulations at constant pressure and/or temperature.J. Chem. Phys.19807242384239310.1063/1.439486
     [Google Scholar]
  26. HessB. BekkerH. BerendsenH.J.C. FraaijeJ.G.E.M. LINCS: A linear constraint solver for molecular simulations.J. Comput. Chem.199718121463147210.1002/(SICI)1096‑987X(199709)18:12<1463::AID‑JCC4>3.0.CO;2‑H
     [Google Scholar]
  27. Al-KhafajiK. Taskin TokT. Molecular dynamics simulation, free energy landscape and binding free energy computations in exploration the anti-invasive activity of amygdalin against metastasis.Comput. Methods Programs Biomed.202019510566010.1016/j.cmpb.2020.10566032726718
     [Google Scholar]
  28. KumariR. KumarR. LynnA. g_mmpbsa-a GROMACS tool for high-throughput MM-PBSA calculations.J. Chem. Inf. Model.20145471951196210.1021/ci500020m24850022
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673322888240718104833
Loading
ORG-317 Repurposing as a Potential Agonist Targeting TMEM236 in Colorectal Cancer Treatment: Insights from Molecular Dynamics Simulation, Principal Component Analysis, and Free Energy Landscape Study
Curr. Med. Chem. 33, 540 (2026); https://doi.org/10.2174/0109298673322888240718104833
/content/journals/cmc/10.2174/0109298673322888240718104833
/content/journals/cmc/10.2174/0109298673322888240718104833
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): Colorectal cancer; drug repurposing; free energy landscape; molecular docking; molecular dynamics simulation; mortality

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test